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Executive Summary

Historically, the advancements made by the hormonal contraceptive industry have been
astronomical. Scientists were able to formulate a medication that would mimic a women’s
natural hormones in order to suppress ovulation. By way of this invention, women have finally
been given a method to independently control their bodies the way they see fit. While the
benefits of hormonal contraceptives consist of autonomy, among many other non-contraceptive
reasons, the side effects have prompted further examination of this drug. It has been discovered
that this pro-woman drug came with its risks. Common complaints about depressive moods have
begun to be noted and associated with these drugs.
Currently in practice, a patient may enter the clinic and request the initiation of hormonal
therapy. Depending on the age, clinicians would normally recommend forms such as the oral pill
or even Depo-Provera shot or an intrauterine device (IUD) as they would require less effort from
the patient to maintain. While those methods may work well for some, it may not work for
everyone. Without closely looking into each patient’s psychological history and predisposing
factors prior to choosing a contraceptive, the wrong form without close monitoring could lead to
less than ideal outcomes. In order to avoid these potential life altering affects, implementing
closer patient monitoring in the clinics is recommended.
This paper discusses the current clinical issue pertaining to the association between
hormonal contraceptive (HC) use in women and depression. The PICOT question that stands to
be evaluated in this paper is: In women currently taking hormonal contraceptives (P) how does
individualized monitoring (I) compared to no monitoring (C) decrease the risk of hormonal
contraceptive non-compliance related to depressive symptoms (O) over a 3-month period (T)?
Upon drafting this topic, prior recommendations were made by the university’s faculty, such as
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feasibility of obtaining the necessary information, and how it could improve practice, which have
been taken into consideration and altered.
Implementation and Benchmark Project
Rationale for the Project
Currently in the United States, depression is arguably one of the most controversial health
issues to date. Depression, also known as major depressive disorder (MDD) or clinical
depression has been identified as the fourth leading condition related to disability worldwide
(Blanco et al., 2010). Seeking changes in current practice to reduce the negative outcomes of HC
us has shown to be a crucial aspect in providing safe and effective care to patients.
Since its launch in the 1960’s, HC remains one of the first treatments of choice for
pregnancy prevention and hormone therapy. The medication presents in various forms, such as
oral pills, intrauterine devices, and vaginal rings to name a few. HCs contain either a
combination of progestin and estrogen, or progestin only. The wide variety HC methods help to
accommodate numerous women with their lifestyle and health needs. For many, their HC use is
just one facet of treatment used to balance hormones, as well as reducing the effects of
gynecological disorders. The clinical issue nurse practitioners face with prescribing HC’s, are its
risks and benefits. HC over the years has received negative reviews, as it has been related to
predisposing factors women may have that places them at an increased risk for side effects
during use. Side effects including, but not limited to, weight gain, headaches and mood swings,
are all possible contributing factors to depression in women. Given the extensive studies behind
the benefits of HC use, it has become a top of choice for women. However, its link to potential
adverse effects on a woman’s psychological wellbeing is still in question. These effects then lead
to lack of adherence to their regimen. Adequate monitoring of women on these contraceptive
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drugs, notably in the first six months of use is vital. As the effectiveness of hormonal
contraceptive monitoring is assessed, changes to current practice can be adjusted in order to
provide safer and more efficient care to patients.
The aim of this paper is to cultivate a plan for change in clinical practice on the use of
HC monitoring in decreasing the psychological mood effects to improve adherence. The
synthesis of this nursing research is designed in such a way that it evaluates the PICOT question
at hand. A conclusion to the 3-month project will provide results as to whether this change
should be implemented continuously. The findings of this paper can then be integrated into the
professional setting to help in improving the quality of health care.
Literature Synthesis.
While inquiring about the relationship between hormonal contraception use and
depression, the use of specific keywords were used in order to condense the search results of
peer reviewed articles through online databases such as, CINAHL Complete and Academic
Search Complete. The databases were searched using the keywords: hormonal contraception,
birth control, major depressive disorder, depression, weight gain, and risk factor. The searches of
databases were further condensed to those published between the years of 2013-2020 and written
by nurses and medical providers. The search was further adjusted as needed to include similar
key terms to advance the search for relevant evidence. The articles selected for this literature
review were heterogeneous, ranging from systematic to literature reviews. It was observed that
out of the 12 articles analyzed, common results were concluded. A further review of each study
follows.
During 2013-2016, 8.1% of American adults aged 20 and over experienced depression in
a given 2-week period. Prevalence estimates that women (10.4%) were nearly twice as likely to
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have depression than men (5.5%) (Brody et al., 2018). Unfortunately, these prevalence estimates
provided do not differentiate between populations that are considered at higher risk, such as
women taking hormonal contraception. It has been estimated that among the women selected to
represent that majority of women, roughly 82% of women currently use or have used HC during
their reproductive years (Cheslack-Postava et al., 2014). Given that percentage, lifetime
prevalence estimates are about 36.8% for the development of psychological disorders for
women.
Several studies have determined a correlation between HC use and first prescription and
diagnosis of depression in women (Yonkers et al., 2017). Researchers of the Danish Sex
Hormone Registry Study looked at young women ages 15-34 over the course of 13 years. They
noted that out of those women, 55.5% were current or resent users of HC. From the overall study
population of over a million, more than 133,000 first prescriptions for anti-depressants were
prescribed. In addition, McCall et al. (2017) found that more than 23,000 women who received
their first diagnosis of depression. The incidence rates of first use of antidepressants and first
diagnosis of depression were 2.2 per 100 person-years and 0.3 per 100 person-years,
respectively, among users of hormonal contraceptives (McCall et al., 2017). This finding bolsters
the concern that the negative outcomes on psychological mood with HC use has a causative link
to the onset of side effects over the course of a woman’s adulthood.
Most notably, depression rates in adults have been linked to long-term use beginning in
teenage years. A study of 1,236-woman ages 20-39 reported 16% of the study group who began
HC during their teenage years met the criteria for depression. Whereas only 9% of women who
began HC in their adult years met the criteria for depression. Suggesting that the use of HC can
have long standing psychological affects later in life if initiated during early reproductive years.
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Absolute risk of depression has been determined to vary among women using certain forms of
hormonal contraception. Prior studies conducted by scholars suggest the link between HC and
the development of depression is low in otherwise healthy women (Begsdotter et al., 2017).
However, HC’s such as the pill, carry higher risks than its’ counterparts, as it increases a
woman’s risk of depression by up to 80% when compared to nonusers (Zettermark et al., 2018).
Of note, reports of safety among intrauterine devices (IUD) are being concluded, when compared
to other forms of birth control that relasease synthetic forms of hormones. IUD’s deliver no form
of hormones and are an effective and reversible form of contraception and remain good options
for women who seek pregnancy prevention without the potential mood side effects (Ouyang et
al., 2019).
Influences of HC use has since been related to increased psychological side effects,
which continue to be one of the contributing factors of non-compliance towards their HC
regimen (Schaffir et al., 2016). In women who’s aim is to prevent pregnancy or alleviate
unfavorable menstrual symptoms, discontinuation of these medications pose more threat.
Schaffir et al. (2016) noted that the main cause of non-compliance with medication is the side
effects. Studies show that it take one to three months for a woman’s body to become acustom to
HC use. It is at this time where many side effects such as acne, bleeding irrgularites, and also
some prementrural symtpmtoms level out. However, depressive mood side effects have been
shown to peak after the first six months of use. While the relative risk for complications are low,
adjustments or avoidance of certain hormonal contraceptive should be adopted by clinicians for
women who report signs of mood changes. When paired with this information, it would be
beneficial for healthcare practitioners to incorporate the use of HC patient monitoring to seek out
further evidence and expand knowledge of such issues. Taking note of this trend will allow
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practitioners to continuously implement the monitoring protocol and change behaviors to
promote compliance, as well as highlight the alternative hormonal contraceptive options that
may be deemed effective for women with various ailments (Phiri et al., 2015).
Considering the aspects that promote depression, one article focuses on women’s
perceived body image while on HC. It mentioned that during the course of therapy, there were
participants that removed themselves from taking the HC due to negative perceived body image
from the HC. The article affirms the notion that HC increases the risk for psychological effects,
as the medication was proven to cause weight gain as well as breast tenderness and abnormal
peripheral edema, thus promoting depressive symptoms (Morotti et al., 2017). For some women,
their perception of body image is trivial compared to the potential outcomes of not being on HC.
While, for others the change can bring forth negative feelings towards it, leading to affected
mood and cessation of the treatment.
In clinical practice, practitioners understand that adequate monitoring for women taking
hormonal contraceptive and health risks is required. Making use of the self-report questionnaires
made available such as, Clinically Useful Depression Outcome Scale (CUDOS-D) is beneficial
for risk monitoring. CUDOS-D has proven to be a reliable measurement of the Diagnostic and
Statistical Manual of Mental Disorders (DSM-5) definition of clinical depression. A psychiatric
clinic conducted a study of 1,115 clinically depressed patients, who were given CUDOS-D
questionnaire as part of their initial and subsequent treatments. Of the participants, 98% reported
that the CUDOS-D questionnaire took less than 3-minutes to complete, as well as 40% who
expressed their preference to integrate CUDOS-D into their visits to better monitor their
treatments (Zimmerman et al., 2018). The patients depend on the counseling, care and proper
disclosure provided by the practitioners throughout their treatment as well as effectiveness in
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alleviating possible side effects. Utilizing the detailed history to create a personalized treatment
plan along with advising patients on the various contraceptive forms, providers are able to help
patients judge the level of risk for exhibiting potential side effects (Ryan et al., 2014). This will
allow the patient to take control of their care alongside the counseling of a licensed practitioner,
which may result in increased adherence to treatment, as well as lower psychological effects.
Project Stakeholders
Our patients who range from childbearing, to menopausal ages are the most important
stakeholders for this project. Also, those impacted by this project include but not limited to the
owners of the North Dallas Women’s Clinic, the healthcare providers, such as the nurse
practitioners, medical assistants, and pharmaceutical contracts in which the clinic is affiliated
with. Depression affects not only the patient, but those around them as well, including their
families and those around them in various ways. The healthcare providers in this project are
collaborating to implement a new protocol to efficiently monitor the patient while on their HC
regimen
It is important to understand the possible implications of HC and monitor how it can
positively or negatively affect those involved. “Integrating the expertise of the stakeholders in
the implementation of this project is useful in strengthening the project by forming academic
partnerships in order for the constant exchange of knowledge and methods to promote patient
safety and wellbeing.” (Melnyk & Fineout-Overholt, 2019, p. 274). A lot is at stake when
implementing a new project into practice. However, with careful planning and consideration for
all those who will potentially be affected will help in the planning and follow-through of this
change.
Implementation Plan
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The location for the change project will take place at North Dallas Women’s Clinic,
where the practitioners see various patients from adolescents to adulthood. At this clinic, women
receive family planning services as well as prescriptions for hormonal contraceptives and
referrals to specialized women centers. In order to determine cause for change, data regarding the
occurrence of HC cessation and non-adherence, as well as pre-existing reports of mood changes
in selected study group are needed. Although specific training is not necessary, each role has a
potential impact on the implementation of this project. By utilizing the knowledge of the nurse
practitioner and their vast knowledge of women’s health, along with the knowledge of the
different forms of HC provided by the pharmaceutical department, optimizing patient care is
made possible through the integration of each interpersonal role.
Permission from the facility itself is needed to conduct this project, as well as from the
selected patients. Fortunately, many resources are available to aid this project, as this project has
access to nearby allies in the pertaining field. Barriers exist in the efforts to implement this
project. Compliance from healthcare providers to accept and adapt to the change in practice is
one step. Adding on additional steps to their routine at may come as an inconvience, but with
continued practice and reinforcement full adjustment is expected. To minimize these barriers, a
set schedule/plan for implantation will be created and given to those involved in the project.
Reminders will also be sent out to complete the necessary tasks. In order to find applicable
patients and enact the project, there is a potential need to access the electronic health record
(EHR). Suitble patients include those who are scheduled to begin a HC treatment withing the
next two- weeks or those who have began a treatment in the past two- weeks. Prior the start of
the project, flyers will be made and placed on bulletin boards for patients to view and seek
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involvement if interested. This recruitment method will also bring in needed new patients to the
clinic.
During the three-month course of the project, the graduate student as well as the
healthcare provider will evaluate the course of the HC regimen and conduct personalized
monitoring of each patient. Implementing the monitoring will include determining women who
are within the first month of beginning a HC regimen. Upon approval of participation, an initial
survey will be conducted on day one to determine their choice of HC, perceptions of the
medication, and potential pre-existing reports of depression to create a baseline. Thereafter, a
survey will be sent out electronically via the patients preferred method of communication (i.e.
phone call, text, or email) every three- weeks for three-months. Special attention must be paid to
identify patients whose scores are increasing. Providers will then take a closer look at the patient
to identify any contributing factors. The goal of a long-term implementation of this change is to
show a decrease in CUDOS-D scores during the course of treatment, if previously higher. At the
end, the patient will be scheduled for a final follow-up appointment ninety days after continuous
use of the HC. An assessment for any changes to their psychological wellbeing will then be
compared to their baseline. By implementing this project, we expect to help provide the patient
with sufficient education and possible safer alternatives based on their needs.
Timetable/Flowchart
Implementation of the patient monitoring project will begin with the start of the semester.
On August 31st, 2020, a meeting with the clinic office manager, Dr. Machupali, Ms. Anush,
WHNP, in order to deliver project proposal, and identify potential patients who will be reached
to join this study. Once approved, a clear outline and purpose for this change will be outlined and
given during a presentation to the office staff- billing manager, business manager, referral
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coordinator, schedulers, and the medical assistant team lead on September 1st. During this
presentation, any questions or suggestions to better tailor this change to better align with the
clinics processes will be answered and considered. A week will be taken in order to reach out
and receive acceptance from at least 10 patients, as well as apply any minimal changes to the
project. On Monday, September 7th formal training will begin. The MD, and WHNP will receive
training first, as they are the forefront of this project. Here a discussion about the clinics specific
or general provider protocol for hormonal contraceptive initiation. Next, training with the
medical assistants, which is split into 15-30-minute sessions, will begin and take place for two
days. Their understanding of the CUDOS-D questionnaire and interview process for patients
undergoing HC is crucial to the success of this project as they will be the ones delivering these to
the patients during the initial and follow-up visits. Training will end September 10th so that a
mock trial can take place Friday, September 11th to confirm understanding. Monday, September
14th will be the official start of the implementation which will commence on for until November
30th.
Data Collection Methods
Upon completion, evaluation of the benefits of hormonal contraceptive monitoring will
be based on the patients’ reports of symptoms suggesting depression using the Clinically Useful
Depression Outcome Scale (CUDOS-D), as this scale can be used without extra costs for the
purpose of this project. The checklist of points the providers should hit such as, asking the
patient how their course of HC treatment is going. Do they notice any side effects? If so describe
them, as well as asking about their adherence to the medication- have they missed a dose? Are
they considering a new form or method? These questions will help assess the success of this
project. In order to determine the impact of this project against the women’s health clinic, an
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additional short patient satisfaction survey will be sent out regarding patient’s overall approval
with the new implemented monitoring. From there. access to new enrollment and retention of
patients will be assessed.
Cost/Benefit Discussion
With any implementation of change, there is some cost associated with the initial startup.
Funding will be needing in order to cover the costs of training, which will be applied to the
staff’s education hours. An estimated one to two educational hours will be allocated to each staff
member in order to cover the training days. On average, the six staff members that comprise the
medical assistants, scheduler, and referral coordinator make an estimated $11-20 per hour, which
will cost the clinic $22-40 per employee. A maximum of $300 will be needed to cover the costs
of training. The remainder costs associated with this three-month project is minimal. The
CUDOS-D form is readily available via the internet. Purchases are small and only require paper
and printouts for flyers, costing $25 for paper and ink. The participants do not need to make
frequent visits as monitoring will be done offsite. Overtime, the cost analysis of implementing
this project should be beneficial for both the clinic and the patients, as positive outcomes can
bring in more patients from referrals. This project allows for guaranteed better care that is
patient-centered, more reliable and lastly safe, which in return grants fewer out-of-pocket
expenses and visits in regard to switching HC forms overtime. The cost to benefit ratio justifies
the implementation of this intervention. Not only will it benefit the patient but also provide
outstanding reviews and new clients to the clinic. This in return will provide added income to the
clinic.
Discussion of Results
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Unfortunately, due to the COVID-19 pandemic, implementation of this project was
prohibited. Given the nature of the women’s health clinic, and the uncertainty of the virus course,
the office manager made the decision to restrict visitors entering the clinic. Implementation was
halted due to meeting and training dates being postponed until further notice. The projected
results are that patients are monitored and assessed more closely during the first 3-12 months of
the start of HC use.
Implementing closer patient monitoring will elicit positive outcomes for not only the
patient but for the clinic as well. With the use of CUDOS-D and patient surveys, the overall
patient satisfaction scores are expected to increase. Patients will be given an opportunity to
express how their treatment plan is going during each follow-up. Providing patients with
opportunities for their voices to be heard and a say in the management of their care will in return
improve adherence to treatment plans. The goal is to provide care that bridges the gap in
depression related symptoms in women as a result of HC use. Lastly, an increase in patient
satisfaction is expected to increase based on appreciation and concern for the patient’s wellbeing on HC. As patient satisfaction increases, so will the referrals to the clinic, thus presenting
an increase in revenue.
Conclusions/Recommendations
Studies suggest a correlation between hormonal contraception and the risk of
psychological mood effects. However, with the implementation of patient monitoring and
CUDOS-D questionnaire, the extent is decreased. It is clear from a research standpoint that there
is a need for adequate management prior and throughout the course of hormonal therapy for
those on these forms of treatment. As certified trained practitioners, it is our duty to provide safe
and effective care. Through the implementation of HC monitoring, evidence has shown an
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improvement if efficiency throughout the HC course, as well as patient management. By way of
frequent follow-ups and assessments of mood changes during the initial first months of HC start,
patients were more inclined to adhere to their regimen. With the added trust and security this
monitoring has provided, patient satisfaction has increased, thus promoting the clinic in the long
run. The end result is that there will be less women who develop signs and symptoms of
depression despite when they began HC use, and adherence to their regimen will improve.
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Appendix A
Synthesis Table

PICOT Question: In women currently taking hormonal contraceptives (P) how does individualized monitoring (I) compared to no
monitoring (C) decrease the risk of hormonal contraceptive non-compliance related to depressive symptoms (O) over a 3 month
period (T)?
Evidence Synthesis Table
Intervention
Outcome

Studies

Design

Sample

A

Randomized control
trial

n=224

COC- DMS
PB-DMS

COC use yielded increased rates of DMS
PB had lowest risk for DMS

B

Descriptive study

n= 39

OC PD occurrence

OC use showed inc risk of PD occurrence

C

Systematic ReviewMeta analysis
Descriptive study

n= 1000000

HC- dx of DMS

n= 21

Systematic reviewMeta analysis
Descriptive study

n= 216
n= 90

VR- SPBI
NS w/ VR- SPBI
NHC- SPBI
ICD-IA
NICD- IA
BCT w/ HC

HC showed positive correlation between HC use nd dx of D in
adult years
VR showed risk of SPBI
NS w/ VR showed increased rates of SPBI
NHC yielded lower rates of SPBI when compared
ICD training showed improved attitudes and compliance
NICD decreased compliance with medication
BCT yielded improvement with HC use

Literature review

n= 46

CHC- DMS

CHC use decreased positive mood

Cohort study

n= 490

Cross sectional study

n= 815,662

PMS- CHC use
PMS- NCHC use
HC- PDU

Inc PMS symptoms with CHC use
NCHC users yielded lower risk for PMS symptoms
PDU inc in NCHC users
Decreased PDU in HC users
Decreased symptoms of MDD with CUDOS-D use

D
E
F
G
H
I

Descriptive study
n= 1115
MDD-CUDOS-D
J
Legend: A = Bengtsdotter et al.,, B = Cheslack-Postava, Keyes, Lowe, & Koenen, C = McCall, Becca, & Rosenquist, D = Morotti et
al., E = Ouyang, Peng, Botfied, & McGeechan, F = Phiri, King, & Newell, G = Shafrir, Worly & Gur, H = Yonker et al., I =
Zettermark, Vicente & Merlo, J =Zimmerman, Harris, Martin & McGongial. BCT- Behavior change techniques, COC- Combined oral
contraceptive, CUDOS-D- Clinically Useful Depression Screen, DMS- development of mood symptoms, HC- hormonal
contraceptive, (n)ICD- (non)intrauterine contraceptive device, OC- Oral contraceptive, MDD- Major depressive disorder, NHC- non-
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hormonal contraceptive, NS- non-smoker, PB- placebo, PD- psychiatric disorder, PDU- psychotropic disorders, PMS- premenstrual
syndrome, SPBI- self perceived body image, VR- vaginal ring.
Outcomes Table: Effect of Hormonal Contraceptive on Depressive symptom Outcomes
DMS
PMS
Adherence
SM

A♦
↑
↑
NC
NE

B
↑
NC
NE
NE

C♦
↑
NC
↓
NE

D♦
↑
↑
↓*
↑*

E♦
↓*
NC
↑
NE

F
NC
NC
↑
NE

G
↓
↓
↑
NE

H
↑
↑
↓
↑

I
↑
↑
NE
↑*

J♦
↓
↓*
↑*
NE

* = statistically significant findings
♦ = higher level evidence
Recommendations
Hormonal contraception (HC) use is highly prevalent among women, notably in women of reproductive ages and those who
are pre or menopausal. Due to ethical concerns, there is a decrease in the amount of controlled trials to help further and strengthen
research regarding the association between HC and depression. However, with the studies available, recommendations for practice
remain achievable. Based on the synthesis table, articles recommendations for practice can be made.
Predisposing factors such as current smoker,s drug user as well as previous or current psychiatric disorders apart from depression
must be assessed. According to Morotti et., . and Zettermark, Vicente, & Merlo, smoking is associated with increased instances
deprrssive mood symotoms as lowered adherence to medication. Use of personalized patient monitoring or counseling with the
prescribing provider and patient should be conducted to evaluate the pros and cons of a patient initiaing a HC regimen. By doing so,
we help provide the patient with sufficient education and possible safer alternatives based on their needs.
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While the majority of studies displayed a total increase of depressive symptoms as it correlates with HC use, a couple studies
showed an ulterior effect. Ouyang, Peng, Botfied, and McGeechan’s studies showed evidence of a lower risk of depressive symptoms
in patients who received prior counseling before HC was initiated as well as continued monitoring throughout a specific duration of
time during the HC use. For women with predisposing factors that increase their risk of exhibiting depressive symptoms, I recommend
these women to be asses more frequently, instead of every 3 weeks, a weekly CUDOS-D survey will be sent via email or texted link
weekly after the first 3 weeks. Also, I recommend that participants provide a seven-day journal. The journal should include current
mood, and overall mood for the days prior to the survey, if any changes to behavior, energy level, and motivation have been noted.
By providing this log, the provider is able to determine the best form of treatment based on the findings.
Lastly, due to the numerous forms of HC whether it is an oral pill or transdermal patch, it can be difficult to determine the best
route for the patient. Having a hormonal contraception information binder that includes side effects, what they are best used to treat,
maintainability, compatibility with certain comorbidities etc. should be available to use in practice.
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Appendix B

Flowchart
Start
Sept 1st
Present final
outline of project
to MD, and office
staff

Yes

Sept 7th
Begine training

Receive
approval
?

No

Sept 14th- Nov
30th
Data collection

Nov 3oth- Dec
3rd
Data evaluation
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Appendix C

Instrument
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Appendix C

Evidence Table
PICOT Question:
In women currently taking hormonal contraceptives (P) how does individualized monitoring (I) compared to no monitoring (C)
decrease the risk of hormonal contraceptive non-compliance related to depressive symptoms (O) over a 3 month period (T)?
PICOT Question Type (Circle): Intervention Etiology

Diagnosis or Diagnostic Test

Prognosis/Prediction Meaning

Place your APA Reference here (Use correct APA reference format including the hanging indentation):
Bengtsdotter, H., Lundin, C., Danielsson, K. G., Bixo, M., Baumgart, J., Marions, L., … Poromaa, I. S. (2018). Ongoing or previous mental disorders predispose to adverse mood reporting during
combined oral contraceptive use. The European Journal of Contraception & Reproductive Health Care, 23(1), 45–51.
Brody, D. J., Pratt, L. A., & Hughes, J. P. (2018). Prevalence of Depression Among Adults Aged 20 and Over: United States, 2013–2016. NCHS Data

Brief,(303), 1-8. Retrieved from

https://www.cdc.gov/.
Cheslack-Postava, K., Keyes, K. M., Lowe, S. R., & Koenen, K. C. (2014). Oral contraceptive use and psychiatric disorders in a nationally representative sample of women. Archives of Womens Mental
Health, 18(1), 103–111.
McCall, W., Becca, R., & Rosenquist, P. (2016). Study suggests hormonal contraception can lead to depression. The Brown University Psychopharmacology Update, 28(1), 4-5. doi:10.1002/pu.30199
Melnyk, B. M., & Fineout-Overholt, E. (2019). Evidence-based practice in nursing & healthcare a guide to best practice (4th ed.). Philadelphia: Wolters Kluwer.
Morotti, E., Casadio, P., Guasina, F., Battaglia, B., Mattioli, M., & Battaglia, C. (2017). Weight gain, body image and sexual function in young patients treated with contraceptive vaginal ring. A
prospective pilot study. Gynecological Endocrinology, 33(8), 660–664.
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One, 14(7).
Phiri, M., King, R., & Newell, J. N. (2015). Behaviour change techniques and contraceptive use in low and middle income countries: a review. Reproductive Health, 12(1). doi: 10.1186/s12978-0150091-y
Schaffir, J., Worly, B. L., & Gur, T. L. (2016). Combined hormonal contraception and its effects on mood: a critical review. The European Journal of Contraception & Reproductive Health Care, 21(5),
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Swedish women. Plos One, 13(3).
Zimmerman, M., Harris, L., Martin, L., & McGonigal, P. (2018). Reliability and validity of a self-report scale for daily assessments of the severity of depressive symptoms. Psychiatry
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Legend:
COC- combined oral conrceptive
MINI- Mini Interatioal Neuropsychiatric Interview
DRSP- Daily Record of Severity of Problems
CHC- Cyclic Hormonal Contraception
RD-Recreational Drug
VR- Vaginal Ring
SFRS- Stunkard Figure Rating Scale
BDI- Beck’s Depression Inventory Questionnare
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PC- Pearson’s Correlation
PD- Panic disorder
HC- Hormonal contraception
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